The food safety risk assessment of GM animals by Kok, E.J. & Jones, W.
 1
The food safety risk assessment of GM animals 
 
 
Esther J. Kok1 and Wendelyn Jones2 
1 RIKILT Institute of Food Safety, Bornsesteeg 45, 6706 AL Wageningen, The Netherlands, esther.kok@wur.nl 
2 Rockville, Maryland, USA 
 
 
 
1. Introduction 
1.1. General  
Over 98% of all genetically modified organisms (GMOs) that have been introduced into the 
environment worldwide are genetically modified plants. Micro-organisms and animals constitute 
only a very limited portion of all GMOs that have been ‘field’-tested so far. This situation may, 
however, change as there are already a number of examples of genetically modified (GM) animals. 
Of these, GM fish varieties are perceived as closest to marketing. So far no GM animals have been 
introduced into either the US or EU market, but depending on regulatory developments and public 
opinion the number of different GM animals bred and marketed world wide may increase.  
 
Two types of GM animals can be distinguished. The first group has been genetically modified to 
enhance overall performance and have, therefore, added value in an agronomic and/or economic 
sense. The whole animal will eventually be available for the food market. The second group of GM 
animals has been transformed to produce specific substances in milk, eggs or blood or serve as 
medical research model. The goal of this later GM technology is the production and isolation of the 
specific substance or tissue as a marketing material or to use the animal for medical research 
purposes or for toxicity testing and ; they are not intended for food production. However, animal 
disposition of these GM animals is still a concern.  In addition, a distinction should be made 
between germ-line modified animals and somatic cell -modified animals. In the latter case only 
specific tissues will have incorporated the new trait(s), whereas the rest of the animal will remain 
genetically unaltered. 
 
When discussing the food safety aspects of GM animals two scenarios should be considered: 1) 
the intentional introduction of GM animals into the food production chain and 2) the unintentional 
introduction of GM animals. Although in the latter case precautions will be taken to avoid GM 
animal materials entering the food production chain, such an unintentional event should 
nevertheless be part of the risk evaluation process.  
 
1.2 Regulatory aspects 
In recent years considerable expertise has been gained in the food safety assessment of GM 
plants. Although work is on-going to optimise current safety assessment approaches, it can be 
stated that solid strategies have already been developed that minimize the possibility of adverse 
health effects for the consumer of GMO-derived plant products. In fact, no adverse effects have 
been observed that can be related to an approved GM plant variety. These food safety assessment 
strategies for crop plant products are based on a series of expert reports initiated by the IFBC 
(1990), that was taken over and carried further by OECD (1993,1996) and FAO/WHO (1991, 1996, 
2000) in order to come to globally agreed safety assessment approaches (FAO/WHO, 2001; Codex 
Alimentarius, 2003). Current safety assessment strategies address a number of different issues 
related directly to the genetic modification as well as to potential unintended side effects of the 
genetic modification on the food organism. In practice, information is asked on 1) the process of the 
genetic modification, 2) the safety of the newly introduced proteins, including information on 
potential allergenicity, 3) occurrence and potential implications of unintended side effects of the 
genetic modification, 4) possible effects of gene transfer and recombination, 5) the role of the new 
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food in the diet and 6) the influence of food processing (Kuiper et al., 2001).  Based on this dossier 
additional questions of food safety may be asked.  
 
The safety assessment of GM animal-derived food materials has also been subject to discussion in 
a number of expert meetings by OECD (1992,1993) and FAO/WHO (1991,1996, 2000) and the US 
National Research Council (NRC, 2002). It was concluded that the minimal food safety assessment 
of GM animals should comprise (Kleter and Kuiper, 2002) 1) the molecular characterisation of the 
inserted foreign DNA, 2) the safety assessment of the introduced genes and their products, 3) any 
unintended effects of the insertion of foreign DNA in the organism, and 4) the effect of disease 
resistance brought about in transgenic food animals on consumer’s exposure to disease-causing 
agents. Depending on the method of gene transfer used, additional questions of food safety will 
have to be answered with relation to the infectivity of the vector, the assessment of potential effects 
of vector regulatory elements on the host cell and the possibility of recombination with endogenous 
viral sequences.   
 
Experience in the safety assessment of GM animals is still very limited, but it is clear that 
evaluators of GM animal-derived food products will benefit from experiences with GM plants as 
basic approaches for GM plant materials also apply to GM food animals. This working paper will 
draw upon the experience in the food safety assessment of GM plants to discuss the food safety 
assessment of GM animal –derived food products.   
 
1.3 Risk assessment approach and limitations 
The traditional paradigm for conducting a risk assessment includes four steps:  hazard 
identification, hazard characterization, exposure assessment and risk characterization (NAS report, 
1983).   With GM animals and derived foods all four steps of the risk assessment must be 
undertaken on a case-by-case basis within this still evolving area. Thus the authors propose a 
comparative safety assessment to enable the final risk characterization.  Drawing from the 
experiences with GM plants, the safety assessment is often a two-tiered approach where initially 
information is gathered to identify parameters and the magnitude of these parameters that 
distinguish the GMO from its traditional counterpart.  The next phase is then to gain further insight 
into the toxicological and nutritional relevance of the detected differences.  These characterization 
steps, when matrixed with the exposure of the hazard, will allow for the final risk assessment.   
        
2. GM animals  
2.1 General   
There are two types of GM animals: those whose alterations are stably incorporated throughout 
their genomes and those with non-heritable transgenic constructs. The former are often referred to 
as “transgenic animals” while the latter techniques are often referred to as “gene therapy”.  Gene 
therapy modifications are not limited to modifications intended only to therapeutically treat animals. 
In fact, the distinction between heritable and non-heritable modifications is not dependent on the 
intent of the modification. Rather, it is a function of the technology chosen for the intended 
modification.  
 
2.2 Methodologies used for gene transfer 
2.2.1. Non-Heritable Modifications  
Animals containing non-heritable changes are produced by the introduction of the gene of interest 
in a vector that targets the somatic cells of the animal.  There are two types of vectors preferentially 
used: those based on viral sequences and those based on transposable elements.   
 
Viral-based technologies take advantage of the integrative properties of retroviruses and 
adenoviruses. The integrative function is the ability of viruses to “cut in” to the sequence of host 
DNA. Such interruptions may be benign or hazardous.  Transposon-based technologies have also 
been developed. Transposons are often referred to as “jumping genes” because of their ability to 
catalyze their own movement within the genome of the animal.  Transposons were first discovered 
in the plant kingdom, but have recently been identified in animals, including humans.  
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Any gene therapy technique may give rise to insertional mutagenesis or unintended gene activation 
or silencing.  The  risk scenario for both viral and transposon-based vectors also includes concern 
for recombining with existing viruses in the intended target animals, in humans who are exposed to 
them, or in other animals that may be exposed to the target animals or their wastes. Recombination 
may give rise to viruses with increased host ranges (swine viruses becoming capable of infecting 
humans), increased virulence (innocuous viruses causing serious illness), or generation of entirely 
new, pathogenic viruses.  
 
2.2.2. Heritable Modifications 
GM animals are produced as the result of the stable incorporation of genetic constructs in their 
nuclear chromosomes or mitochondrial genomes. In general, transgenic animals are produced by 
injecting early embryos with solutions of DNA that contain constructs that have all of the requisite 
information for directing the expression of the gene(s) of interest, but rely on the cell’s internal 
recombinatory enzymes for integration. Scientists have also used viral vectors or transposon-based 
vectors to produce transgenic animals with heritable traits. 
 
Production of a transgenic line of animals is usually a two-step process. Mosaic transgenic animals 
are produced by the introduction of the transgenic construct into early stage embryos. The 
expectation is that most of the cells of that developing embryo will contain the gene of interest, 
including some germ cells. These animals are considered “mosaics” as they are composed of two 
or more genetically distinct cells. Mosaics are then bred and the offspring tested to find animals 
with 100% transgenic cells (i.e., derived from a transgenic germ cell in the mosaic).  A founder 
animal, in which all cells carry the transgene, is selected and bred to propagate the transgenic line.  
 
2.3 Genetically Modified Animals and Their Products 
2.3.1 Laboratory Models 
GM animals are now common tools used to investigate the mechanisms of both normal physiology 
and the pathophysiology of humans and animals. An example is the pig model for human retinitis 
pigmentosa, a progressive disease that begins with night blindness. This model is intended to help 
develop pharmaceutical strategies to slow the onset and progression of the disease. 
 
2.3.2 Biopharm Modification in Food-Animals 
2.3.2a Human therapeutic agents 
GM animals can be developed as bioreactors for the production of therapeutic proteins. In general, 
these protein products will be produced in the animal’s milk (cows, sheep, and goats), eggs 
(chickens), semen (swine), or blood (large farm species). The advantages of producing these 
products in animals rather than cell or tissue cultures include high yields, mammalian glycosylation 
pattern and lower post-development costs (Ziomek, 1998).  Examples of therapeutic products from 
GM animals include alpha-1-antitrypsin (ATT) in goat milk. This human blood protein is intended to 
treat hereditary emphysema (ATT deficiency), cystic fibrosis, and chronic obstructive pulmonary 
disease (Colman,1999). Other examples include antibody production in GM animals for diagnostic 
and medicinal purposes from milk or blood (Houdebine, 2002).  
 
2.3.2b. Xenotransplantation 
The field of xenotransplantation covers many procedures, ranging from implantation of single cells 
to treat Parkinson’s disease to the transplantation of organs to treat organ failure. GM animal organ 
transplantation has yet to be successfully implemented in humans, although transplants of smaller 
tissues and individual cells are currently under active clinical investigation.  Because of their 
physiological similarities to humans, pigs are attractive as a potential organ donor species. 
Because tissue rejection appears to be the primary medical barrier, pigs have been modified to 
knock-out 1, 3-galactosyl transferase, a protein linked to acute human tissue rejection. 
 
2.3.2c Industrial Products 
The use of GM animals in the production of industrial products provides a novel “manufacturing” 
source, and a number of challenges to manufacturers, regulators, and the public. Perhaps the best 
known example is transgenic goats producing spider silk proteins in their milk. These proteins could 
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be used in the manufacture of body armor.  The larger part of this category of transgenic animals 
will be kept in containment and it is essential that they should not enter the food production chain. 
Nevertheless the unintended entry into the food supply chain should be part of the risk assessment 
procedure prior to the breeding of these GM animals. 
 
2.3.3 Agronomic Modification in Food Animals 
2.3.3a  Animal Health and Productivity 
The most well-known products in this category are those incorporating growth hormone 
(somatotropin) genes into the genomes of the same or other species. Aquaculture provides several 
good examples. The main traits to be altered are growth rate, cold tolerance, disease resistance 
and sterility. Transgenic salmon, catfish, carp and tilapia have been developed to reach market 
weight sooner than their non-transgenic counterparts by using fish-derived somatotropin.  
(However, earlier research involved somatotropins from other sources. The promoters used can be 
either tissue-specific or constitutive (Maclean, 2003).  For cold tolerance antifreeze proteins, such 
as winter flounder-derived delta-9-desaturase, have been tested, but have not yet proved 
successful (Maclean, 2003).  
 
Disease resistance in animals can also be enhanced using GM techniques. Lysostaphin, a 
bacteriocidal enzyme, has been introduced into cows to decrease the incidence of mastitis caused 
by Staphylococcus aureus. Moth cecropin, a broad spectrum antimicrobial peptide, has been 
transgenically incorporated into catfish to decrease their susceptibility towards a broad range of 
bacterial diseases (Zhang et al., 1998).  
 
2.3.3b  Enhanced animal nutrition 
Enhanced animal nutrition and growth performance by modification is possible.  For example, 
bovine lactalbumin and insulin-like growth factor-1 (IGF-1) have both been introduced into sow milk 
for the improvement of the growth characteristics of the piglets (Wheeler et al., 2001).  Attempts in 
fish are ongoing to alter the carbohydrate metabolism of especially salmonoids in order to be able 
to use vegetable products in the aquacultural systems (Maclean, 2003).  The “Enviropig” is another 
example of GM that affects the nutrition of the pig. In this specific case, phytase is introduced into 
pigs to allow them to make better use of the phosphorus in their feed. This not only allows the 
farmer to decrease phosphate supplements, but also decreases the amount of phosphorus in pig 
manure. (Golovan et al., 2001)  
 
2.3.3c Human Foods 
Foods derived from GM animals can be altered with respect to functionality and composition. For 
example, cows can be modified to make a more desirable milk: (1) producing milk more digestible 
for lactose intolerant individuals by lowering its lactose content, or (2) increasing the amount of a 
naturally occurring antimicrobial enzyme to increase the shelf life of milk. Althought the meat 
industry also has increasing interest in the improvement of the sensory and nutritional quality of 
their meat  products (Garnier et al., 2003), few GM experiments are currently performed in this area 
as yet.  
 
Fish can also be modified to provide better, more nutritious food. One example is the transgenic 
modification of rainbow trout to increase the amount of the omega-3 fatty acid that they produce 
and store. 
3. Comparative safety assessment   
3.1 Principle of substantial equivalence, applied      
The principle of substantial equivalence was originally described by the FAO/WHO (1991), and 
subsequently named and detailed by the OECD (1993). The rationale behind the principle is that 
many food products we eat today are derived from organisms that we can not consider inherently 
safe. Nevertheless, we have been consuming these products for decades without any obvious 
deleterious effects. Because of this history of safe use, it is generally acknowledged that traditional 
food products should serve as a baseline for comparison and that novel GMO-derived food 
products should be at least as safe as the traditional products that they may replace in the diet. The 
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principle has lead to much debate in recent years as interpretation of the principle differed between 
countries. Nevertheless, the basic idea of comparing new GMO-derived products with closely 
related traditional counterparts to assess the safety of the newly developed organisms is 
unchallenged.  Substantial equivalence should represent a starting point of the assessment rather 
than the end point (Kuiper et al, 2002) and should not be confused with being an absolute safety 
standard. 
 
Application of the principle is usually a tiered approach, a Comparative Safety Assessment (CSA, 
Kok and Kuiper, 2003) where the initial step is comprised of a thorough comparison with the closely 
related traditional counterpart. This comparison includes both phenotypic characteristics as well as 
a compositional analysis. The phenotypic analysis should also include factors such as disease 
resistance to common diseases. Information should be supplied on:  
- the transformation process of the genetic modification, including the sequence of the inserted 
material,  
- the copy number and place(s) of insertion,  
- stability of the integration,  
- the safety of any newly introduced proteins, including allergenicity,  
- occurrence and implications of unintended effects,  
- potential effects of gene recombination,  
- the role of the new GM animal food in the diet and  
- the influence of processing on the new GM food product.  
Within Europe, sequence analysis of the place(s) of insertion is also part of initial phase of the 
CSA. More precise criteria for the molecular characterisation are currently being discussed in the 
OECD.  
 
3.2  Hazard Identification and Characterization 
The hazard identification step is typically the first step in any risk assessment.  However, for 
complex GMO-derived foods, the hazard identification step will not be as readily completed as in 
the case of well-characterised single chemical compounds.  Similarly, the hazard characterization is 
not as readily determined with complex GMO-derived foods. The variety and magnitude of 
unintended effects when testing complex food products, whether GMO-derived or not, may 
preclude straightforward hazard identification and characterization. The differences found as a 
result of the CSA serve as comparable to the hazard identification and hazard characterization 
steps in a traditional risk assessment paradigm.  
 
3.3 Gene Transfer 
The DNA construct used to change the genetic make-up of the animal should be considered within 
an assessment especially if the gene or its promoter is derived from a viral source since horizontal 
transfer or recombination may occur.  Additionally, bacterial host-derived materials may contain 
additional sequence fragments unrelated to the target gene.  Because such fragments can be 
heterogenous in size and sequence, they are difficult to detect.  This is particularly a problem with 
retroviral vectors.  Host cells often contain large numbers of endogenous viruses and virus-like 
sequences (Chakraborty et al 1994; Scadden et al 1990, NAS hazard report).  Inadvertant 
introduction of such sequences into the germline of a GMO not only has the potential for creating 
unintended genetic damage but can also contribute by recombination to the generation of novel 
infectious viruses.  A well known example is the generation of a replication-competent murine 
leukemia virus (MLV) during the growth of a vector containing a globin gene (Purcell et al., 1996).  
In a similar way prions may be introduced to the GM animal or derived products (Faber et al., 
2003). 
 
Furthermore, there is potential for horizontal transfer of the gene construct: food-ingested foreign 
DNA may not be completely degraded in the gastrointestinal tract of mice (Schubbert et al., 1997; 
Schubbert et al., 1998). It was shown that phage M13 mp18 DNA  following oral ingestion by mice 
may reach peripheral leukocytes, the spleen and liver via the intestinal wall mucosa and was 
covalently linked to mouse DNA (Schubbert et al., 1997). Similar results were obtained when a 
plasmid containing the gene for the green fluorescent protein was fed to mice (Schubbert et al., 
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1998).  However, these results have been criticized due to the complication of artifacts within the 
methodology (Beever and Kemp, 2000). For the food safety assessment it is prudent to assume 
that DNA fragments may survive the human gastrointestinal tract and be absorbed by either the gut 
microflora or somatic cells lining the intestinal tract.  
 
Commonly used marker genes are genes that code for antibiotic resistance. Risk assessment of 
these selectable genes should focus on gene transfer to microorganisms residing in the gastro-
intestinal tract of humans or animals. There is general agreement that transfer of antibiotic 
resistance genes from plants to human gut micro flora is unlikely to occur and impact antibiotic 
efficacy (FAO/WHO 1996, 2000; Van den Eede et al.). Similarly, the likelihood of such transfer from 
GM animals to human gut microflora will also be low.  However, as the potential of gene transfer 
can not be completely ruled out, the safety assessment should also consider information on the 
role of the antibiotic in human and veterinary medical uses.  Furthermore, within the EU the use of 
antibiotic resistance marker genes in newly developed GMO-derived food products is not allowed.  
 
3.4 Safety of the gene product 
The safety of the gene product must be assessed on a case-by-case basis. Depending on the 
knowledge on the expressed product the assessment may range from a limited evaluation process 
of the available data on the protein, such as amino acid sequence and expression rates in different 
tissues, to, in the case of less well-documented proteins, extensive toxicity testing including animal 
studies. In theory, the advent of GM animals may lead to the introduction of many new proteins 
without a history of safe use into the human diet. The assessment of the novel proteins should be 
based on current knowledge of toxic substances, including a search for sequence homology with 
known toxins, and the function of the novel protein. In the case of unknown proteins a full classic 
toxicological safety assessment procedure will form part of the evaluation. 
 
In this respect a distinction should be made between GM animal-derived food products that were 
developed, to improve agronomic characteristics and GM animal-derived food products developed 
for veterinary, pharmaceutical or industrial purposes. So far the number of different genes that is 
used for the production of GM food animals is still rather limited when compared with plants, but 
this situation may change with the progress of genome sequencing programmes that are likely to 
provide a wealth of data on important animal physiological pathways.   
 
3.5 Allergenicity  
Food whether developed by conventional means or through biotechnology is a potential source of 
allergens.  All food allergies are mediated by antigen-specific IgE and are characteristic of type-I 
reactions.  In the case of new proteins being expressed in the GM animal, the allergenic potential 
of the protein will need to be established. In the case of production of specific well-characterised 
(medicinal) proteins by the GM animal, it needs to be established whether the post-translational 
modifications are comparable to the same substances being produced by more traditional sources 
in order to assess potential altered toxicological or allergenic properties of the newly synthesized 
proteins (Dyck et al., 2003).  
  
Efforts to characterize the mechanisms of allergies at both cellular and molecular levels, have 
produced only a limited understanding of the characteristics that allow a protein to induce 
sensitisation or a full allergenic reaction. Because of these complexities, it has long been 
recognized that there is no single parameter that can predict the allergenic potential of a substance. 
Recently, the strategy to address allergenicity of biotechnology products has been formulated 
(FAO/WHO, 2001; Metcalfe et al, 1996, Codex Alimentarius, 2003), which relies on the following 
parameters: source of the gene, sequence homology, serum testing of patients known to be 
allergenic to the source organism or to sources distantly related, pepsin resistance, the prevalence 
of the trait and animal models. 
  
The source of the introduced protein should be part of the background material available to conduct 
an allergenicity assessment.  Allergenic sources of genes would be defined as those organisms for 
which reasonable evidence of IgE mediated oral, respiratory, or contact allergy is available.  
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Knowledge of the source of the introduced protein allows the identification of tools and relevant 
data to be considered in the allergenicity assessment.  (Codex Alimentarius, 2003) 
  
Sequence homology is the initial step in the allergenicity assessment.  When sequence homology 
to a known allergen is demonstrated, the product is considered allergenic and no further testing is 
typically undertaken.  The FAO/WHO panel recommended using an amino acid window for the 
sequence homology that was scientifically justifiable.  Research reports showed that an amino acid 
window size of less than eight amino acids may result in a high rate of false positives (Hileman, 
2002).  
  
Specific serum screening is then undertaken irrespective of the prevalence of allergy to the source 
material in question when the source is a known food allergen.  When no sequence homology has 
been found between the expressed protein and an allergen, targeted serum screening (direct 
source and related organisms) is undertaken.  The use of larger numbers of sera is advocated 
whenever possible to increase the confidence associated with the results.    
  
Additional assessment of the potential allergenicity of expressed proteins may be performed by 
pepsin degradation analysis or by using animal models.  Pepsin digestion stability is believed to 
impart on the allergen an increased probability of reaching the intestinal mucosa intact where 
absorption of significant quantities may lead to sensitization. Protein stability in itself is, however, 
not sufficient to exclude potential allergenic properties as exceptions are known of less stable 
proteins that are allergenic. There are several animal models including the intraperitoneal (IP) 
murine model and the Brown Norway rat model.  Failure to elicit IgE antibody production after IP 
administration to the laboratory mice where immunogenicity is evident on the basis of IgG response 
may provide some reassurance that the protein lacks a significant potential to provoke allergic 
sensitization. In practice the predictive value of these systems for proteins that are new to the 
human diet may, however, be limited (König et al.).  
  
3.6 Unintended effects 
Potential unintended effects represent a significant concern with GMOs including GM animals and 
these effects highlight the difficulty of establishing uniform considerations instead of case-by-case 
considerations.  Unintended effects can be divided into insertional effects, related to the place of 
insertion of the transgenic fragment, and secondary effects, related to the nature of the expression 
products of the introduced genes.  The major approach to detect any unintended side effects in the 
GM animal is a phenotypical and compositional analysis to compare the new food organism with 
the traditional counterpart.  Whereas, there are databases on plant species describing the current 
knowledge (including a listing of (natural variation in) macro and micronutrients, natural toxins and 
other anti-nutritional factors) (OECD, 2003), a comparable database is not as readily available for 
food animals.   
 
For GM animal-derived food products the same approach should apply. The edible tissues of the 
GM animal under investigation and comparable tissues from a genetically related non-GM animal 
should be phenotypically and compositionally analysed and screened for differences that may have 
toxicological or nutritional relevance. Similar to the GM plants, the key constituents of the tissue 
would have to be established. Because of the likeness between animals and humans, few animal 
tissue constituents can be considered anti-nutrients or natural toxins, but there are exceptions, 
such as thiaminase in different fish species and tetrodotoxin in puffer fish (Kleter and Kuiper, 2002). 
An important difference with GM plants is the average number of off-spring from one GM animal. 
The number of GM animals derived from a single GM founder animal will in general be much lower 
compared to GM plants. As the associated costs will be considerable, the selection process of the 
initial founders will be very limited compared to the plant breeding situation where thousands of GM 
calluses are screened for incorporation of the transgenic fragment and subsequently monitored for 
their phenotypic characteristics.  This means that the information on the variation range between 
animals with the same genetic modification will be rather limited and that detected differences 
between individual animals will be difficult to interpret. In theory, the consequence of the smaller 
number in animal breeding may be that the selection process is less stringent with GM animals 
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which may lead to higher chances for unintended effects.  On the other hand, however, GM 
animals may be more vulnerable to smaller changes in their physiology and therefore selected 
transgenic organisms without obvious phenotypic aberrations may show relatively few physiological 
alterations when compared to GM plants. Further research may shed more light on these aspects 
with relation to the safety assessment.  
 
As the number of key nutrients and/or anti-nutrients is limited in any species, a targeted 
compositional analysis will have its limitations in the information that can be provided. For animal 
products where there is no tradition of composition analysis, unbiased profiling methodologies that 
are currently being developed may become a valuable addition to the present targeted approaches 
as part of the food safety assessment strategy, once they are validated (Kuiper et al., 2003).  The 
issue of sampling is crucial for both the targeted and profiling approach. For comparative 
compositional analyses, it is very important that the conditions for breeding of the animal and 
sampling of the edible animal parts are highly similar to avoid the detection of differences that are 
unrelated to the genetic modification.  Animal tissues have to be analysed before any processing 
has taken place. At the same time, any potential effects of the subsequent processing steps should 
also be included in the overall risk evaluation.   
 
There is likely to be expanded work in profiling food derived from GMOs including GM animals for 
safety evaluations as part of a CSA.  The profiling approach can be roughly divided into holistic 
approaches on three different integration levels: genomics, proteomics, and metabolomics. 
 
3.6.1 Genomics  
Microarray technology is a powerful tool to study gene expression.  The technology allows 
comparison of expression profiles of a large number of genes under different environmental or 
developmental conditions.  CDNA or EST (expressed-sequence tag) libraries can be established of 
any organism under investigation (Kok and Kuiper, 2003).  If alterations in gene expression are 
found, the nature of the related gene will provide initial information on the toxicological or nutritional 
relevance of the alteration. Detected differences should be confirmed by additional targeted 
analysis preferably aiming also at the corresponding proteins or metabolites.  The main advantage 
of the gene expression microarray approach over proteomic and/or metabolomic approaches is the 
scale of study. Where proteomics or metabolomics are likely to include at best 10% of the proteome 
or metabolome, respectively, the gene expression microarray makes it feasible to study whole 
transcriptomes of the organism.  
 
3.6.2 Proteomics  
Proteomics is the direct counterpart to transcriptomics.  In general, correlation between mRNA 
expression and protein levels is rather poor as the rates of degradation of mRNA and proteins differ 
(Gygi et al., 1999).  Therefore, understanding the biological complexities underlying gene function 
is facilitated by analysis of many proteins simultaneously.  Methods used for analyzing differences 
in protein patterns include SDS-PAGE followed by peptide mass fingerprinting. There are, however, 
limits to what 2DGE can analyse as, in general, only highly expressed proteins will be detected 
(Gygi et al., 2000).   Another approach that is currently being tested is the use of isotope-coded 
affinity tags to analyse fragmented proteins or multidimensional liquid chromatography coupled to 
mass spectrometry 
(http://www.foodstandards.gov.uk/science/research/NovelFoodsResearch/g02programme/g02proje
ctlist/g02001).  Also a protein microarray approach to accomplish the same end is under 
development based on the interactions of individual proteins with their substrates or with other 
proteins. This development may lead in time to ‘whole proteome’ approaches that may reduce the 
necessity for initial gene expression profiling (MacBeath et al., 2000; Templin et al., 2002). 
 
3.6.3 Metabolomics  
Continuing down the cascade from genome and proteome is the metabolome. The metabolome 
consists of the metabolites that occur within a biological entity. A multi-compositional analysis of 
biologically active compounds (metabolites) may also indicate the presence of unintended effects.  
Metabolites can be determined by traditional chemical techniques including gas chromatography 
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(GC), high pressure liquid chromatography (HPLC), coupled to mass spectrometry (MR) or nuclear 
magnetic resonance (NMR). These methods are capable of detecting, resolving, and quantifying a 
wide variety of compounds in a single sample. This type of chemical fingerprinting provides more 
details than can be obtained by single compound analysis.  Once differences are observed these 
differences should be further analyzed by in vitro or in vivo testing.  Before chemical fingerprinting 
can be readily exploited to determine substantial equivalence as related to GMO-derived foods, 
efforts to standardize sample collection and extraction are needed.  Once again, background data 
on non-GMO comparator sources should be collected to acquire knowledge on the natural 
variability of the species.   
 
3.7 Toxicology          
In general, it will not be possible to test complex animal products by classical toxicological animal 
studies in the way they are routinely used to test single compounds. Classical studies measuring 
physiologic response relative to dose are complicated if the laboratory animal is receiving doses of 
the GM animal’s edible tissue. If the genetic modification would result in the expression of novel 
proteins or if the compositional analysis revealed an alteration in an endogenous protein product or 
metabolite, the traditional toxicological approach would require the concentration of the product to 
be elevated in the laboratory animal’s diet to the extent that the diet will often become unbalanced. 
This might result in toxicological observations that are unrelated to the product under investigation. 
To avoid this scenario, the concentration of the product can only take place within the limits of 
national and international recommendations on optimal laboratory animal diets, thereby limiting the 
sensitivity of the tests  (Barlow et al., 2002; Cockburn, 2002).  On occasions where the genetic 
modification results in an increase in a specific (exogenous) protein, for instance directly derived 
from the gene construct, traditional testing would still be valid to assess that portion of the derived 
food.  Alternatively, there may be instances wherein endogenous protein levels in the GM food are 
increased well above physiologic level in the given animal species and it might be prudent in 
specific cases to (also) test this elevated protein in animal studies.   .    
 
3.8 Nutritional analysis         
The nutritional analysis should focus on the potential replacement of nutritionally important food 
products by the novel GM animal-derived food products with possibly altered characteristics. The 
information for the nutritional analysis will largely be derived from the initial CSA, including the 
compositional analyses (especially macro-, micro- and anti-nutrients) and the estimated 
consumption rates. Detected alterations in the GM animal-derived food products compared to the 
traditional counterpart will be assessed by evaluating the significance of the compositional 
differences for the consumer in general and also, in specific cases, for specific consumer groups. 
Nutritional aspects of GMO-derived foods may become of increasing significance when the number 
of compositionally altered food products on the market increases. Therefore, the nutritional 
assessment of GM animal-derived food products is dependent on current consumption data of 
animal-derived food products in distinctive consumer groups and with respect to geographical and 
demographical differences. Special consumer groups perhaps worthy of special consideration 
include children, pregnant or lactating women and elderly persons.  
 
Micronutrients are vitamins and minerals that are essential for normal physiology and biochemical 
functioning.  Both deficiency and excess of a micronutrient can cause health problems which 
emphasizes the importance of this class of compounds. Macronutrients include dietary lipids, 
proteins and carbohydrates and these classes of compounds are present in the food and diet in 
substantial quantities. Assessment of the replacement factor of important animal-derived sources of 
micro- and macronutrients by GM animal products in the event of altered composition with relation 
to these nutrients is therefore of major importance. Bioavailability of the important micro- and 
macronutrients from GM animal-derived tissues is also of significant importance in this respect.  
 
4.  Exposure Assessment         
To assess the amount of food or food ingredient an individual or group is exposed to, represents 
the goal of an exposure assessment. No exact criteria have been formulated so far for the factors 
considered in an pre-market exposure assessment of a complex novel food product. Some 
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exposure paradigms make assumptions based on per capita production while others use per capita 
distribution.  An exposure assessment may also consider the cooking and food preparation process 
used.  Some governments have instituted tracking of animal derived food and from this dataset, 
post-market consumption data may be determined. Exposure assessments will also include an 
estimate of the extent to which current food products will be replaced by the GM animal-derived 
novel food product. Thus, the accuracy of the exposure assessment for GMO-derived foods is 
dependent upon the available data on consumption patterns in consumer groups of interest and the 
validity of the underlying parameters (Kuiper 2001).   
 
The potential exposure of children of different age groups to growth factors in GM fish-derived 
tissues is an actual example as this GM animal-derived food product is requesting market entry in 
the US. The exposure assessment will be based on available consumption data and our knowledge 
on the bioavailability of the growth factors upon consumption. Mathematical models for integrating 
food consumption and distributions may be used in a so-called probabilistic approach to estimate 
future exposures more precisely.  Alternatively, biomarker based methodologies for quantifying 
exposure to food chemicals are garnering interest but this approach is not yet validated for 
traditional food additives much less for GMO-derived food (Kroes et al., 2002). 
 
5.  Risk Characterization          
Risk characterization typically refers to the probability that a hazard would produce a given adverse 
effect.  Risk characterization is the stage of risk assessment that integrates information from 
exposure assessment and hazard characterization into advice suitable for use in decision making 
or risk management.  It is prudent to highlight that risk characterization is typically viewed as an 
iterative and evolving process.  With traditional food additives the risk characterization can take the 
form of establishment of an allowable daily intake level (ADI).   
 
In the case of GMO-derived food the many facets of the CSA and the exposure assessment would 
need to be matrixed together. The baseline for the safety of novel food products derived from 
GMOs, including GM animals, in all cases will have to be the assessment that the novel GM 
animal-derived food products is at least as safe as its traditional counterpart. If any questions 
remain after the initial CSA with respect to the safety of the GM animal-derived food products 
additional tests may be required, including animal studies with the whole product or selected 
tissues/extracts. If, after a full safety assessment, the safety standard can not be satisfied the GM 
animal-derived product should not be approved for marketing. For food products derived from GM 
food animals this characterization should be established on a case-by-case basis.  
 
5.1 Post-Marketing surveillance   
Closely related to the risk characterization is the issue of post-marketing surveillance.  Post market 
surveillance could be useful in certain instances where a better estimate of dietary exposure and/or 
nutritional consequence of GMO-derived food are required. In general, potential safety issues 
should be addressed adequately through pre-market studies. However, given the complexities of 
food allergies it is conceivable that, for instance, allergenicity concerns could warrant post-market 
surveillance (Hlywka et al, 2003) as part of the risk management profile.  
 
For GM animal-derived medicinal substances existing pharmacovigilance schemes will apply to 
monitor any unforeseen unintended side effects of the isolated medicinal substances. The same 
would apply in a veterinary sense with respect to the GM animal itself when modified with respect 
to the production of hormonal or disease-prevention substances: pharmacovigilance schemes 
could help to detect unintended side effects of the introduced expression product to the GM food 
animal that were not detected in the pre-market phase. To this end the GM animals should then be 
included in such pharmacovigilance schemes on the basis of ‘internal’ administration of the specific 
veterinary substance.  
 
Post-marketing surveillance systems for GM animal-derived food products need the establishment 
of adequate traceability systems of the GM animal products in the food production chain. Here, the 
food animal sector has clear advantages over the crop plant sector where basic traceability 
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systems for individual farms, let alone plants, is still virtually lacking. In the animal production 
sector, such systems are already well-established for some animal food production chains in some 
countries and many other initiatives are ongoing in this field.  
 
Traceability will in practice be most feasible for well-characterised GM animals dedicated for the 
production of specific substances or tissues that are kept in containment. Safety precautions 
should, however, be aimed at the prevention of any introduction of these GM animals into the food 
supply chain.The precautions should also include the development of analytical tests for detection 
and identification.  
 
It is important to note that traceability and related control systems may be less straightforward in 
the case of chimeric organisms as different parts of the food animal will have different genetic 
constitutions and this may severely complicate analytical control of traceability systems.  
 
Depending on the questions and risk management needs underlying the establishment of post-
marketing surveillance systems the information conveyed to the consumer may, however, require 
adjustment.  In order to enable consumers to relate potential adverse, for instance allergenic, 
effects to a GM animal-derived food product, it will be necessary to not only label the product as 
GMO-derived, but also provide information on the specific GM animal source, for instance by 
including in the label the unique identifier code specific for a single founder animal and its off-
spring.  
 
6. Conclusions  
The food safety evaluation of GM animals and derived products can largely be performed along the lines 
that have already been established for the evaluation of GM plants and derived products for the 
consumer. This means that the initial step of the food safety evaluation will be a CSA of the GM animal 
with its traditional counterpart, if available. This approach identifies potential differences between the GM 
animal-derived food products and its traditional counterpart as the first phase. The next phase is then to 
gain further insight into the toxicological and nutritional relevance of the detected differences.  As every 
GM (founder) animal at this moment will have a different genetic constitution with respect to the 
integration of the genetic construct, the safety evaluation should be carried out on a case-by-case basis, 
even if the same genetic construct was used for the genetic modification. If homologous recombination 
will reduce the possibility of insertional effects in the future, it may become more feasible to come to more 
harmonised approaches for the safety assessment of GM animals and products thereof.     
 
Application of the concept of substantial equivalence allows for analysis of intended and 
unintended alterations in the GMO and is central to the CSA.  The intended changes can be 
evaluated with knowledge of: the nature and source of the gene construct used in the modification, 
the process of  the genetic modification, in situ characterization of the genetic modification in the 
animal, information on animal breeding and propagation of the GM animal, the amino acid 
sequence of expressed product from the gene construct, the expression rates in different tissues of 
the expressed product, and traditional toxicological testing of the expressed product.  
 
In addition the food safety evaluation should focus on possible unintended side-effects of the 
genetic modification. Unintended effects can be divided into insertional effects, related to the place 
of insertion of the gene fragment, and secondary effects, related to the nature of the transcription 
products of the introduced genes. Allergenicity represents a possible hazard that most likely is an 
unintended effect of the modification of a food animal. To detect any unintended effects a 
comparative phenotypical and compositional analysis of the new food organism and the 
conventional counterpart should be carried out. This should currently be based on the known key 
micro- and macronutrients and anti-nutrients, if applicable, and may in the future also be based on 
unbiased profiling of the GMO-derived food and traditional counterpart. Techniques for the profiling 
approach are now under development and can be divided into three subsections: genomics, 
proteomics, and metabolomics to screen for differences in the GM animal with relation to the gene 
transcription products, proteins and metabolites, respectively.  At this moment, however, none of 
these techniques is yet validated and ready for routine use in risk assessment. If applied, 
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depending on the identity of differences detected further toxicological testing may be required to 
assess the safety and nutritional impact of the observed differences. 
 
A few major differences can be seen when comparing the GM animal to the GM plant situation. 
Firstly, the numbers of GM animals derived from a single GM founder animal will in general be 
much lower compared to GM plant genetic modification events and numbers available in 
subsequent plant generations. This will result in less animals being available for the comparative 
safety assessment. This will have major influence on the reliability of the results of the comparative 
safety assessment. Knowledge on the natural background variation in animal tissue constituents 
will even be more important compared to the plant situation as it will be less feasible to obtain 
statistically significant results from analysis of the GM animals versus the conventional counterpart.  
An additional difference is the omnipresence of natural toxins in plant products and the very few 
cases of animal products that have proved to contain antinutritional substances for the consumer.  
 
A third difference relates to the traceability systems that are (will be) available in the animal 
production sector and not yet in the plant sector. The presence of these traceability systems will 
make proper post-marketing surveillance systems much more feasible compared to the plant 
situation. Post-marketing surveillance studies may be advocated in the case of uncertainties 
relating to the nutritional or exposure assessment of the product or, in exceptional cases, to the 
potential allergenicity of the newly introduced protein(s). Other health- and nutrition-related aspects 
should be sufficiently dealt with during the pre-market assessment. Depending on the questions 
underlying a post-marketing study it may, however, be necessary in order to meet the goal, of the 
study to add information on the GM source animal to the label and inform the consumer of this 
additional label information.  
 
Current food safety regulations for traditionally food (or food additives) are less stringent compared 
to those applied to GM foods.  Pre-market safety assessment of GMO-derived foods must provide 
sufficient safety assurances, also in the case of GM animals or products derived thereof. The use 
of post-marketing surveillance as an instrument to gain information on the long-term effects of food 
either GMO derived or traditional should be further explored, but the requirement of routine 
application will entail large costs for limited amounts of information and should therefore be limited 
to exceptional cases.   
 
The fact that the physiology of animals has major resemblance to our own physiology may in some 
aspects make the assessment of (GM) animal-derived food products ‘easier’. On the other hand 
animal-derived food products form an important part of the human diet. Relatively small 
compositional changes may therefore have considerable effects on the nutritional status of the 
consumer. With increasing numbers of genetically altered plant- and animal derived food products 
the nutritional aspects, beside the safety aspects, will increasingly gain weight. The new 
developments in the area of GM animals further necessitate a harmonised approach to maintain 
our current standard for a safe and nutritious food supply in the light of growing numbers of 
different (GMO-derived) foods and food ingredients and increasingly complex food supply chains.    
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